Company Thesis
While there are over 50 million visits to U.S. hospitals for acute pain each year, AcelRx's (ACRX) new DSUVIA launch in Q12019 has only managed to capture $2.4 million in sales at its trailing two-quarter run-rate annualized. Current standards for acute pain management such as IV morphine/fentanyl are just as competent as DSUVIA, DZUVEO, and ZALVISO at just a fraction of its cost. Sublingual delivery of sufentanil poses little significance in surgical settings and cancer treatment due to the synergistic use of anesthesia along with painkillers. Nonetheless, this method of delivery